• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OmniAb Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8/25/25 7:05:25 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    8-K
    NASDAQ false 0001846253 0001846253 2025-08-24 2025-08-24 0001846253 us-gaap:CommonStockMember 2025-08-24 2025-08-24 0001846253 us-gaap:WarrantMember 2025-08-24 2025-08-24
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 24, 2025

     

     

    OMNIAB, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40720
      98-1584818
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    5980 Horton Street, Suite 600

    Emeryville, CA

      94608
    (Address of principal executive offices)   (Zip Code)

    (510) 250-7800

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common stock, par value $0.0001 per share   OABI   The Nasdaq Global Market
    Warrants to purchase common stock   OABIW   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01.

    Entry into a Material Definitive Agreement.

    On August 24, 2025, OmniAb, Inc. (“OmniAb” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 21,254,106 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $1.40 per Share or with respect to any Purchaser that is an officer, director, employee or consultant of the Company $1.85 per Share. The aggregate gross proceeds from the Private Placement are expected to be approximately $30.0 million, before deducting placement agent fees and offering expenses. The Private Placement is expected to close on August 26, 2025, subject to customary closing conditions. The Private Placement is being conducted in accordance with applicable Nasdaq rules.

    The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes.

    Leerink Partners acted as placement agent for the Private Placement.

    Pursuant to the Purchase Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) within 45 days after the closing of the Private Placement (subject to certain exceptions) for purposes of registering the resale of the Shares, to use its reasonable best efforts to have such registration statement declared effective within the time period set forth in the Purchase Agreement, and to keep such registration statement effective until the earliest of (i) the time as all of the Shares purchased by the Purchasers pursuant to the terms of the Purchase Agreement have been sold pursuant to the registration statement, or (ii) such time as the Shares become eligible for resale by non-affiliates without any volume limitations or other restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”).

    Pursuant to the Purchase Agreement, the Company and the Company’s executive officers and directors agreed not to sell or otherwise dispose of any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, for 60 days (or with respect to the Company, the earlier of 60 days after the date of the Purchase Agreement or the effective date of the registration statement).

    The Purchase Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act, and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such Purchase Agreement and are made as of specific dates; are solely for the benefit of the parties (except as specifically set forth therein); may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Purchase Agreement, instead of establishing matters as facts; and may be subject to standards of materiality and knowledge applicable to the contracting parties that differ from those applicable to investors generally. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company.

    The Private Placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Purchasers represented that they were accredited investors within the meaning of rules promulgated under the Securities Act and were acquiring the securities for investment only and with no present intention of distributing any of such securities or any arrangement or understanding regarding the distribution thereof. The securities were offered without any general solicitation by the Company or its representatives. The securities sold and issued in the Private Placement will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements.

    The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.


    Item 3.02.

    Unregistered Sales of Equity Securities.

    The disclosures set forth in Item 1.01 above are incorporated by reference into this Item 3.02.

     

    Item 7.01.

    Regulation FD Disclosure.

    On August 25, 2025, the Company issued a press release announcing that it has entered into the Purchase Agreement. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

    In accordance with General Instruction B.2 of Form 8-K, the information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

       Description
    10.1    Securities Purchase Agreement, dated August 24, 2025, by and between OmniAb, Inc. and each of the purchasers party thereto
    99.1    Press Release of OmniAb, Inc., dated August 25, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    Forward-Looking Statements

    OmniAb cautions you that statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to statements regarding: the timing, size and expectation of the closing of the Private Placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the Private Placement and the anticipated use of proceeds therefrom. Actual results may differ from those set forth in this Current Report on Form 8-K due to the risks and uncertainties inherent in our business, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the private placement and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        OMNIAB, INC.
    Date: August 25, 2025     By:  

    /s/ Charles S. Berkman

        Name:   Charles S. Berkman
        Title:   Chief Legal Officer and Secretary
    Get the next $OABI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Berkman Charles S sold $15,766 worth of shares (8,044 units at $1.96) and converted options into 15,621 shares, increasing direct ownership by 2% to 377,071 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    12/9/25 9:02:55 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Executive VP, Finance and CFO Gustafson Kurt A converted options into 46,500 shares and sold $46,887 worth of shares (23,922 units at $1.96), increasing direct ownership by 10% to 252,688 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    12/9/25 9:02:09 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Foehr Matthew W converted options into 26,554 shares and sold $26,785 worth of shares (13,666 units at $1.96), increasing direct ownership by 0.30% to 4,360,083 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    12/9/25 9:01:14 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Platform Technologies Drive $211B Surge in Precision Cancer Treatment

    Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer drug revenues, reflecting investor confidence in technologies that engineer specific biological outcomes[2]. Companies deploying proprietary platforms to target previously undruggable proteins are capturing premium valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc.

    12/11/25 10:17:00 AM ET
    $ERAS
    $FHTX
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Biological Products (No Diagnostic Substances)

    OmniAb to Hold OmniUltra Virtual Investor Event on December 15

    OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What:   OmniUltra Launch Virtual Investo

    12/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Higgins John L bought $107,707 worth of shares (77,261 units at $1.39), increasing direct ownership by 3% to 2,929,148 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    11/10/25 8:30:36 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/15/25 4:02:17 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/14/25 5:04:09 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    SEC Filings

    View All

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    12/8/25 7:17:46 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    12/8/25 7:15:23 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by OmniAb Inc.

    144 - OmniAb, Inc. (0001846253) (Subject)

    12/8/25 7:14:33 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on OmniAb with a new price target

    RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

    11/29/23 7:31:15 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Benchmark Company initiated coverage on OmniAb with a new price target

    The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

    4/21/23 7:43:22 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Craig Hallum initiated coverage on OmniAb with a new price target

    Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

    4/13/23 9:08:06 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Financials

    Live finance-specific insights

    View All

    Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

    First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today OmniAb, Inc. (NASDAQ:OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215018419/en/ OmniUltra is a versa

    12/15/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Hold OmniUltra Virtual Investor Event on December 15

    OmniAb, Inc. (NASDAQ:OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an overview of this innovative and pioneering technology platform, its market use and applications, as well as its strategic importance to the business. Conference Call and Webcast Information What:   OmniUltra Launch Virtual Investo

    12/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. "Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio. Importantly, OmniAb's innovative technology platform and operational model

    11/4/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Leadership Updates

    Live Leadership Updates

    View All

    OmniAb Appoints Steve Love to its Board of Directors

    OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

    11/1/23 9:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

    SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

    11/14/24 4:06:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

    SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

    7/2/24 5:00:16 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care